MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1542/peds.2016-2193

Медицинская библиотека · Pediatrics · 2017

Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine.

Cohn Amanda C, MacNeil Jessica R, Harrison Lee H, Lynfield Ruth, Reingold Arthur, Schaffner William, Zell Elizabeth R, Plikaytis Brian, Wang Xin, Messonnier Nancy E, Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Meningococcal conjugate vaccines were licensed beginning in 2005 on the basis of serologic end points and recommended for use in adolescents. A single dose at age 11 to 12 years was expected to provide protection through late adolescence. We conducted a case-control evaluation of vaccine effectiveness (VE) and duration of protection of a meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D).

METHODS

Cases of culture- or polymerase chain reaction-confirmed serogroup A, C, W, and Y meningococcal disease among adolescents were identified through meningococcal disease surveillance sites in the United States from January 1, 2006, through August 31, 2013. Attempts were made to enroll 4 friend and school controls per case. VE was calculated using the generalized estimating equation, controlling for underlying medical conditions and smoking.

RESULTS

Serogroup C accounted for 88 (49%), serogroup Y 80 (44%), and serogroup W 13 (7%) of enrolled cases. Thirty-six (20%) cases and 87 (44%) controls received MenACWY-D. The overall VE estimate 0 to 8 years postvaccination was 69% (51% to 80%); VE was 79% (49% to 91%) at <1 year, 69% (44% to 83%) at 1 to <3 years, and 61% (25% to 79%) at 3 to <8 years. VE was 77% (57% to 88%) against serogroup C and 51% (1% to 76%) against serogroup Y.

CONCLUSIONS

MenACWY-D was effective in the first year after vaccination but effectiveness waned 3 to <8 years postvaccination. The estimates of VE from this evaluation informed the Advisory Committee on Immunization Practices in its decision to add a booster dose of MenACWY.

Для цитирования: Cohn Amanda C, MacNeil Jessica R, Harrison Lee H, Lynfield Ruth, Reingold Arthur, Schaffner William, Zell Elizabeth R, Plikaytis Brian, Wang Xin, Messonnier Nancy E, Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine.. Pediatrics. 2017. DOI: 10.1542/peds.2016-2193.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.